D. Warren

Allen R. Chen, H. Uno, Lee-Jen Wei, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia

P. Richardson, P. Armand, S. Treon, 2015, Leukemia.

Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenström's Macroglobulinemia

P. Richardson, S. Rodig, L. Varticovski, 2010, Clinical Cancer Research.

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2014, Blood.

Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome.

Allen R. Chen, Zhezhen Jin, P. Richardson, 2002, Blood.

High Response Rates and Encouraging Time-to-Event Data with Lenalidomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Final Results of a Phase I/II Study.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2009 .

Tailoring treatment for multiple myeloma patients with relapsed and refractory disease.

N. Munshi, J. Laubach, P. Richardson, 2010, Oncology.

Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma

J. Laubach, P. Richardson, C. Mitsiades, 2021, Blood Cancer Journal.

Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study

N. Munshi, P. Richardson, C. Mitsiades, 2013, British journal of haematology.

Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma

L. Trippa, N. Munshi, J. Laubach, 2019, American journal of hematology.

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.

Diane Warren, Edie Weller, S. Jagannath, 2006, Blood.

Phase II Trial of the mTOR Inhibitor RAD001 in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: The Dana Farber Cancer Institute Experience.

P. Richardson, D. DeAngelo, E. Jacobsen, 2008 .

Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer.

D. Fairclough, A. Elias, L. Schnipper, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia.

S. Treon, I. Ghobrial, Z. Hunter, 2014, Blood.

Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia

P. Richardson, S. Treon, I. Ghobrial, 2010, American journal of hematology.

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2010, Blood.

A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer

G. Demetri, P. Richardson, R. Joyce, 2001, Bone Marrow Transplantation.

Prospective, Multicenter Study Of The Mtor Inhibitor Everolimus (RAD001) As Primary Therapy In Waldenstrom’s Macroglobulinemia

R. Advani, S. Treon, I. Ghobrial, 2011 .

Phase II trial of combination of bortezomib and rituximab in relapsed and/or refractory Waldenstrom macroglobulinemia.

P. Richardson, I. Ghobrial, S. Padmanabhan, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The potential benefits of participating in early‐phase clinical trials in multiple myeloma: long‐term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib

J. Laubach, P. Richardson, C. Mitsiades, 2012, European journal of haematology.

Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide–bortezomib combinations

N. Munshi, J. Laubach, P. Richardson, 2015, British journal of haematology.

Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.

D. Esseltine, S. Jagannath, N. Munshi, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation.

P. Richardson, K. Stevenson, P. Armand, 2008, Blood.

macroglobulinemia neuropathy-sparing approach for treating Waldenström's Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a

I. Ghobrial, J. Castillo, Guang Yang, 2014 .

Carfilzomib, Rituximab and Dexamethasone (CaRD) Is Highly Active and Offers a Neuropathy Sparing Approach For Proteasome-Inhibitor Based Therapy In Waldenstrom’s Macroglobulinemia

S. Treon, I. Ghobrial, Z. Hunter, 2013 .

Phase II Trial of Single Agent Panobinostat (LBH589) In Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia

P. Richardson, S. Treon, I. Ghobrial, 2010 .

A Prospective Multicenter Study Of The Bruton’s Tyrosine Kinase Inhibitor Ibrutinib In Patients With Relapsed Or Refractory Waldenstrom’s Macroglobulinemia

R. Advani, J. Laubach, S. Treon, 2013 .

Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia.

P. Richardson, S. Treon, I. Ghobrial, 2009 .

Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Untreated Patients with Waldenstrom's Macroglobulinemia.

P. Richardson, S. Treon, I. Ghobrial, 2009 .

Lenalidomide Plus Bortezomib (Rev-Vel) in Relapsed and/or Refractory Multiple Myeloma (MM): Final Results of a Multicenter Phase 1 Trial.

S. Jagannath, N. Munshi, P. Richardson, 2006 .

Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Encouraging Efficacy in High Risk Groups with Updated Results of a Phase I/II Study

D. Esseltine, S. Jagannath, A. Jakubowiak, 2008 .

High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma.

C. Shapiro, P. Richardson, A. Elias, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer: sequential phase I/II studies

P. Richardson, D. McDermott, R. Joyce, 2001, Bone Marrow Transplantation.

A Phase 1 Trial of Lenalidomide (REVLIMID®) with Bortezomib (VELCADE®) in Relapsed and Refractory Multiple Myeloma.

S. Jagannath, N. Munshi, P. Richardson, 2005 .

Defibrotide (DF) for the Treatment of Severe Veno-Occlusive Disease (VOD) and Multi-System Organ Failure (MOF) Post SCT: Final Results of a Phase II, Multicenter, Randomized Study and Preliminary Analyses of Surrogate Markers and Ultrasound Findings.

Zhezhen Jin, P. Richardson, E. Guinan, 2004 .

Phase II Trial of Weekly Bortezomib in Combination with CCI-779 (temsirolimus) in Relapsed or Relapsed/Refractory Multiple Myeloma.

R. Vij, N. Munshi, J. Laubach, 2009 .

Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy In Relapsed Or Relapsed/Refractory Multiple Myeloma

N. Munshi, J. Laubach, P. Richardson, 2010 .

Phase I Clinical Trial of Oral Administration of the Histone Deacetylase (HDAC) Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) in Patients with Relapsed/Refractory Multiple Myeloma (MM).

N. Munshi, P. Richardson, N. Mitsiades, 2004 .

Phase II Trial of Single Agent Bortezomib (VELCADE®) in Patients with Previously Untreated Multiple Myeloma (MM).

D. Esseltine, P. Wen, S. Lonial, 2004 .

Phase I Trial of CCI-779 (Temsirolimus) and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma

R. Vij, N. Munshi, J. Laubach, 2008 .

Final Results of the Phase I/II Trial of Weekly Bortezomib In Combination with Temsirolimus (CCI-779) In Relapsed or Relapsed/Refractory Multiple Myeloma Specifically In Patients Refractory to Bortezomib

A. Jakubowiak, R. Vij, N. Munshi, 2010 .

Defibrotide (DF) for the Treatment of Severe Veno-Occlusive Disease (sVOD) and Multi-Organ Failure (MOF) Post SCT: Final Results of a Multi-Center, Randomized, Dose-Finding Trial.

Zhezhen Jin, P. Richardson, E. Guinan, 2006 .

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2014, Blood.

Ibrutinib in previously treated Waldenström's macroglobulinemia.

R. Advani, N. Harris, J. Aster, 2015, The New England journal of medicine.

Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia.

P. Richardson, S. Rodig, F. Azab, 2013, Blood.